Immune Checkpoint Inhibitors Clinical Trials

7 actively recruiting trials

▲ +1 trial since August 2026

Pipeline

Phase 2: 2Phase 4: 1Phase 1/2: 1

Top Sponsors

ZSky Biotech Inc1
University Hospital, Basel, Switzerland1
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology1
Shunda Du1
Peking Union Medical College Hospital1

Indications

Cancer7
Immune-Related Adverse Events2
Advanced Solid Tumor2
Liver Disease1
Inflammatory Myopathies1

Other7 trials

A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis

Phase 2

Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients

Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC

Phase 2

Personalized Neoantigen-pulsed Autologous Dendritic Cell Injections for Malignant Solid Tumors

N/A

Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma

Phase 1/2

Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors

Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.